| dbo:abstract |
Die Elan Corporation war ein irisch-amerikanisches Biotechunternehmen mit 400 Mitarbeiten (Stand 2012); Ende 2007 hatte die Firma 2000 Mitarbeiter. Elan hat sich auf Krankheiten des Zentralnervensystems wie Multiple Sklerose, Alzheimer-Krankheit und Parkinson-Krankheit spezialisiert, stellt aber auch Antibiotika her. Elan kooperierte mit Biogen, dem nach Genentech und Amgen drittgrößten Biotechunternehmen der Welt. Gemeinsam brachten beide Unternehmen 2005 das MS-Medikament Tysabri auf den Markt, mussten dies jedoch aufgrund eines Todesfall bereits nach kurzer Zeit wieder vom Markt nehmen. Nach der Einreichung gemeinsamer Anträgen zum erweiterten Einsatz von Tysabri im Januar 2013 kaufte Biogen für 3,25 Milliarden Dollar seinem Partner Elan dessen 50 %-Anteil an den Tysabri-Rechten ab und beendete das Kooperationsabkommen. Im Bereich der Alzheimer-Forschung arbeitet Elan an Inhibitoren der Gamma- und Beta-Sekretase, welche die Entstehung der Krankheit verhindern könnten. Das Unternehmen ist Mitglied im ISEQ Overall Index an der Irish Stock Exchange. Im Dezember 2013 gab Perrigo den Abschluss der Übernahme von Elan für 8,6 Milliarden US-Dollar bekannt. (de) Elan Corporation plc was a major drugs firm based in Dublin, Ireland, which had major interests in the United States. It was listed on the New York Stock Exchange as ELN, the Irish Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L. In 2013, the company merged with Perrigo to form Perrigo Company PLC. (en) |
| dbo:fate |
Acquired byPerrigo (en) |
| dbo:foundingYear |
1969-01-01 (xsd:gYear) |
| dbo:keyPerson |
dbr:CEO dbr:Chairman |
| dbo:location |
dbr:Dublin |
| dbo:product |
dbr:Ziconotide |
| dbo:revenue |
200000.0 (dbd:usDollar) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Elan.png?width=300 |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageExternalLink |
http://elan.com/ |
| dbo:wikiPageID |
654526 (xsd:integer) |
| dbo:wikiPageLength |
7139 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1118106166 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Athlone dbr:Perrigo dbr:Phase_III_clinical_trial dbr:Rheumatoid_arthritis dbr:US_dollar dbr:United_States dbr:United_States_dollar dbr:Don_Panoz dbr:Investor dbr:Public_company dbr:Neurodegeneration dbc:2013_mergers_and_acquisitions dbr:County_Westmeath dbr:Crohn's_disease dbr:Amyloid_plaques dbc:Pharmaceutical_companies_established_in_1969 dbr:Neuropathology dbr:Multiple_sclerosis dbr:Antibody dbr:London_Stock_Exchange dbr:Ziconotide dbr:Pain dbr:Stock dbr:Bapineuzumab dbr:CEO dbc:Manufacturing_companies_based_in_Dublin_(city) dbc:Pharmaceutical_companies_of_Ireland dbc:Pharmaceutical_companies_disestablished_in_2013 dbr:Gamma_secretase dbr:Accounting_scandal dbc:Companies_formerly_listed_on_the_New_York_Stock_Exchange dbr:Dublin dbr:Alzheimer's_disease dbc:2013_disestablishments_in_Ireland dbr:Euro dbr:Parkinson's_disease dbr:Biogen_Idec dbr:Athlone dbc:1969_establishments_in_Ireland dbc:Companies_formerly_listed_on_the_London_Stock_Exchange dbc:Companies_formerly_listed_on_Euronext_Dublin dbr:Chairman dbr:Autoimmunity dbr:Immunotherapy dbr:Inflammatory_bowel_disease dbr:Natalizumab dbr:Neuropathy dbr:New_York_Stock_Exchange dbr:Semagacestat dbr:Wyeth dbr:Irish_Stock_Exchange dbr:Neurology dbr:Neurotoxicity dbr:Phase_II_clinical_trial dbr:Beta_secretase |
| dbp:defunct |
2013 (xsd:integer) |
| dbp:fate |
Acquired by Perrigo (en) |
| dbp:foundation |
Athlone, County Westmeath, Ireland (en) |
| dbp:industry |
Biotechnology (en) |
| dbp:keyPeople |
Kelly Martin, CEO (en) Robert Ingram, Chairman (en) |
| dbp:location |
Dublin, Ireland (en) |
| dbp:logo |
Elan.png (en) |
| dbp:name |
Elan Corporation plc (en) |
| dbp:netIncome |
$ million USD (en) |
| dbp:operatingIncome |
$ million USD (en) |
| dbp:products |
dbr:Ziconotide AZACTAM (en) In pipeline: (en) MAXIPIME for Injection (en) NANOCRYSTAL technology (en) TYSABRI (en) |
| dbp:revenue |
$0.2 million USD (en) |
| dbp:tradedAs |
NYSE:ELN (en) |
| dbp:type |
dbr:Public_company |
| dbp:wikiPageUsesTemplate |
dbt:! dbt:Authority_control dbt:Infobox_company dbt:Other_uses dbt:Reflist dbt:Short_description dbt:Use_Irish_English dbt:Use_dmy_dates |
| dct:subject |
dbc:Athlone dbc:2013_mergers_and_acquisitions dbc:Pharmaceutical_companies_established_in_1969 dbc:Manufacturing_companies_based_in_Dublin_(city) dbc:Pharmaceutical_companies_of_Ireland dbc:Pharmaceutical_companies_disestablished_in_2013 dbc:Companies_formerly_listed_on_the_New_York_Stock_Exchange dbc:2013_disestablishments_in_Ireland dbc:1969_establishments_in_Ireland dbc:Companies_formerly_listed_on_the_London_Stock_Exchange dbc:Companies_formerly_listed_on_Euronext_Dublin |
| gold:hypernym |
dbr:Firm |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatBiotechnologyCompanies yago:WikicatCompaniesBasedInDublin(city) yago:WikicatCompaniesOfIreland yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 |
| rdfs:comment |
Elan Corporation plc was a major drugs firm based in Dublin, Ireland, which had major interests in the United States. It was listed on the New York Stock Exchange as ELN, the Irish Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L. In 2013, the company merged with Perrigo to form Perrigo Company PLC. (en) Die Elan Corporation war ein irisch-amerikanisches Biotechunternehmen mit 400 Mitarbeiten (Stand 2012); Ende 2007 hatte die Firma 2000 Mitarbeiter. Elan hat sich auf Krankheiten des Zentralnervensystems wie Multiple Sklerose, Alzheimer-Krankheit und Parkinson-Krankheit spezialisiert, stellt aber auch Antibiotika her. Im Bereich der Alzheimer-Forschung arbeitet Elan an Inhibitoren der Gamma- und Beta-Sekretase, welche die Entstehung der Krankheit verhindern könnten. Das Unternehmen ist Mitglied im ISEQ Overall Index an der Irish Stock Exchange. (de) |
| rdfs:label |
Élan (en) Elan Corporation (de) |
| owl:sameAs |
freebase:Élan http://d-nb.info/gnd/10037813-4 wikidata:Élan dbpedia-de:Élan dbpedia-fa:Élan dbpedia-sq:Élan https://global.dbpedia.org/id/LyvD http://viaf.org/viaf/132864368 |
| prov:wasDerivedFrom |
wikipedia-en:Élan?oldid=1118106166&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Elan.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Élan |
| foaf:name |
Elan Corporation plc (en) |
| is dbo:wikiPageRedirects of |
dbr:Elan_Corp._Plc dbr:Elan_Corporation dbr:Elan_Corporation,_plc dbr:Élan_Corporation dbr:Élan_Corporation_plc |
| is dbo:wikiPageWikiLink of |
dbr:Biogen dbr:Bitolterol dbr:Dennis_J._Selkoe dbr:List_of_Ireland-related_topics dbr:Perrigo dbr:Richard_Fuisz dbr:DOV_Pharmaceutical dbr:Vertamae_Smart-Grosvenor dbr:Don_Panoz dbr:List_of_off-label_promotion_pharmaceutical_settlements dbr:Tax_inversion dbr:Corporation_tax_in_the_Republic_of_Ireland dbr:Endless_Forms_Most_Beautiful_World_Tour dbr:Garo_H._Armen dbr:Gerald_Weissmann dbr:Chiquita dbr:Ziconotide dbr:Zonisamide dbr:Max_Staegemann dbr:Bapineuzumab dbr:GAA_125 dbr:Jesse_Eisinger dbr:Lary_Walker dbr:Acorda_Therapeutics dbr:DAMS dbr:Celtic_Tiger dbr:Michael_Freund_(historian) dbr:ELN dbr:Assertio_Therapeutics dbr:Tagg_Romney dbr:Economy_of_San_Diego dbr:Elan dbr:Dopexamine dbr:St._Aloysius_College,_Athlone dbr:Semagacestat dbr:ISEQ_20 dbr:Sid_Gilman dbr:Elan_Corp._Plc dbr:Elan_Corporation dbr:Elan_Corporation,_plc dbr:Élan_Corporation dbr:Élan_Corporation_plc |
| is dbp:workInstitutions of |
dbr:Gerald_Weissmann |
| is foaf:primaryTopic of |
wikipedia-en:Élan |
